World's Best Scientists 2026 revealed!
Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
128
Citations
76185
World Ranking
2667
National Ranking
66

Michele Cavo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michele Cavo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,170 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michele Cavo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michele Cavo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 128 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Michele Cavo is affiliated with the University of Bologna in Italy and has a substantial body of work in medical research, particularly focusing on hematology and oncology. Their research spans a variety of fields including Medicine, Biochemistry, Genetics and Molecular Biology, with notable contributions in hematology and molecular biology.

The scientist has a strong emphasis on multiple myeloma research and treatments, protein degradation and inhibitors, and peptidase inhibition and analysis. Additional areas of focus include acute myeloid leukemia, myeloproliferative neoplasms, chronic myeloid leukemia, and chronic lymphocytic leukemia research.

Key recent publications feature studies on multiple myeloma therapies and clinical practice guidelines, including:

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma, 2021, New England Journal of Medicine
  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma, 2023, New England Journal of Medicine
  • Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma, 2023, New England Journal of Medicine
  • Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study, 2020, The Lancet Haematology

Michele Cavo frequently co-authors with several researchers in the field, including Meletios Α. Dimopoulos, Philippe Moreau, Elena Zamagni, María-Victoria Mateos, and Mario Boccadoro. Collaborations with these colleagues are reflected in prolific publication records and ongoing contributions to hematological research.

Their work has been published across multiple specialized and high-impact journals, including Blood, Clinical Lymphoma Myeloma & Leukemia, HemaSphere, Journal of Clinical Oncology, and Haematologica. These venues illustrate the broad dissemination and recognition of their research within clinical and molecular hematology communities.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Philippe Moreau;Tamás Masszi;Norbert Grzasko;Nizar J Bahlis

  • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

    Michele Cavo;Paola Tacchetti;Francesca Patriarca;Maria Teresa Petrucci

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

    María-Victoria Mateos;Meletios A. Dimopoulos;Michele Cavo;Kenshi Suzuki

  • Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

    Antonio Palumbo;Roman Hajek;Michel Delforge;Martin Kropff

  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Lotfi Benboubker;Meletios Athanasios Dimopoulos;Angela Dispenzieri;John Catalano

  • Autologous transplantation and maintenance therapy in multiple myeloma

    Antonio Palumbo;Federica Cavallo;Francesco Di Raimondo

  • Systemic Cardiac Amyloidoses Disease Profiles and Clinical Courses of the 3 Main Types

    Claudio Rapezzi;Giampaolo Merlini;Candida C. Quarta;Letizia Riva

  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos

  • Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Michel Attal;Paul G. Richardson;S. Vincent Rajkumar;Jesus San-Miguel

  • IMWG consensus on risk stratification in multiple myeloma

    W J Chng;A Dispenzieri;C-S Chim;R Fonseca

  • Proteasome inhibitors in multiple myeloma: 10 years later.

    Philippe Moreau;Paul G. Richardson;Michele Cavo;Robert Z. Orlowski

  • Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

    Elena Zamagni;Francesca Patriarca;Cristina Nanni;Beatrice Zannetti

  • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Commentary

    Michele Cavo;S. Vincent Rajkumar;Suzanne R. Hayman;Martha Q. Lacy

Frequent Co-Authors

Giovanni Martinelli
Giovanni Martinelli University of Bologna
Antonio Palumbo
Antonio Palumbo University of Turin
Michele Baccarani
Michele Baccarani University of Bologna
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Mario Boccadoro
Mario Boccadoro University of Turin
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Sante Tura
Sante Tura University of Bologna
Maria Teresa Petrucci
Maria Teresa Petrucci Sapienza University of Rome
Francesco Di Raimondo
Francesco Di Raimondo University of Catania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medicine but seeking flexible, cost-effective education, online healthcare degrees open up numerous career opportunities. A popular entry point is exploring medical billing and coding classes online, which prepare you for administrative roles in healthcare without a clinical background.

If you’re considering direct patient care, there are options for aspiring nurses at every level. Students can begin their journeys with the cheapest online nursing program options, teaching essential nursing skills for entry-level positions. Experienced nurses looking to advance their roles and responsibilities may pursue the cheapest online acute care nurse practitioner programs, ideal for those wanting to provide higher levels of care or specialize in acute health settings.

For nurse leaders, educators, and researchers, obtaining top-level credentials is also accessible. The cheapest dnp programs cater to professionals seeking the highest practice-focused degree in nursing—all through online study. These pathways make healthcare professions attainable for more students, regardless of location or schedule.

Best Scientists Citing Michele Cavo

Trending Scientists

Recently Published Articles